EUROPE OPHTHALMIC DRUGS MARKET 2023-2030

Lifesciences | Pharmaceuticals

EUROPE OPHTHALMIC DRUGS MARKET 2023-2030

Market by Type, Market by Type, Condition, Therapeutic Type, Delivery Method, Channel, and Country Outlook | Forecast 2023-2030

Request For Customization

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

Triton’s research report states that the Europe ophthalmic drugs market is expected to generate revenue at a CAGR of 6.25% over the forecast period 2023-2030.


Report scope can be customized per your requirements - Request Free Sample Report

The countries studied in this region include:

•        United Kingdom

•        Germany

•        France

•        Italy

•        Spain

•        Poland

•        Rest of Europe

The European ophthalmic drugs market is witnessing a dynamic shift due to aging demographics, commitment to the healthcare sector, and pharmaceutical innovations which propels the need for using ophthalmic medications. The future of the studied market seems promising as several companies look forward to collaborating and developing patient-centric medicines. The advancements in medical science and research incentives also create a conducive environment for the growth of the ophthalmic drugs market.

The United Kingdom (UK) holds the highest share in Europe. This is due to an added importance for the healthcare system with regular checkups and early detection of eye diseases. These initiatives lead to a higher awareness among patients to seek early treatment to cure eye disorders. Moreover, the innovations and advancements in drug delivery and treatment options offer convenient ways to manage eye conditions for patients. All these factors together drive the ophthalmic drugs market’s growth in the UK. 

The growth of the ophthalmic drugs market in Italy is attributed to technological innovation, patient-centric eye care for the aging population, and strategic collaborations. A rise in ophthalmic treatments also includes gene therapies and regenerative medicines, which require the usage of ophthalmic drugs. The regulatory standards by the Italian Medicines Agency ensure that manufacturers strictly comply with the norms and maintain quality assurance of ophthalmic products. Additionally, the awareness of telemedicine and e-health services influences the ophthalmic drugs market.

A higher prevalence of dry eye is found in urban areas, especially among the adult population having sedentary lifestyles. The treatment of dry eye involves medication in the form of artificial tears, prescriptions, and lifestyle modifications to address insufficient tear production and preserve eye health. The ophthalmic drugs market is segmented based on type, condition, delivery method, therapeutic type, and channel. The condition segment is categorized into dry eye, glaucoma, retinal disorders, infection, and other conditions.

The key companies in the ophthalmic drugs market are Pfizer Inc, Sun Pharmaceutical Industries Ltd, Thea Pharma Inc, Novartis AG, AbbVie Inc, Bausch Health Companies Inc, Regeneron Pharmaceuticals Inc, Accutome Inc, Genentech Inc, and Johnson & Johnson.

Pfizer Inc is a biopharmaceutical company involved in developing and manufacturing products to treat cancer, inflammation, immune disorders, cardiovascular, metabolic, pain, and rare diseases. The company sells its products in Europe, Africa, South America, Asia-Pacific, and North America. It is headquartered in New York, the United States, with manufacturing facilities in Italy, Germany, Ireland, etc.


KEY DELIVERABLES OF THE REPORT:

      Market CAGR during the forecasting years 2023-2030

      Detailed data highlighting key insights, industry components, and market strategies

      Comprehensive information and estimation of the ophthalmic drugs market revenue growth in Europe and its influence on the parent market

      In-depth study of forthcoming trends in consumer behavioral patterns

      A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces

      A wide-ranging study of factors that will challenge the Europe ophthalmic drugs market’s growth during the upcoming years

Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT
ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET 2022-2028
Lifesciences

ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET 2022-2028

Market by Type, Application, E ..

VIEW REPORT

Table of Content

1.    EUROPE OPHTHALMIC DRUGS MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. TECHNOLOGY SNAPSHOT

2.2. IMPACT ANALYSIS ON THE OPHTHALMIC DRUGS MARKET

2.2.1. COVID-19 IMPACT ON THE OPHTHALMIC DRUGS MARKET

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTES

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. THREAT OF COMPETITIVE RIVALRY

2.4. MARKET MATURITY ANALYSIS

2.5. REGULATORY FRAMEWORK

2.6. KEY BUYING IMPACT ANALYSIS

2.7. KEY MARKET STRATEGIES

2.7.1. COLLABORATIONS

2.7.2. PRODUCT LAUNCHES

2.7.3. MERGERS & ACQUISITIONS

2.8. MARKET DRIVERS

2.8.1. AGING POPULATION VULNERABLE TO EYE DISORDERS

2.8.2. PROGRESS IN DRUG DELIVERY TECHNOLOGIES

2.8.3. ESCALATING INCIDENCE OF OCULAR DISEASES

2.8.4. REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS

2.9. MARKET CHALLENGES

2.9.1. CHALLENGING TIMELINES FOR PRODUCT APPROVAL

2.9.2. ADVERSE EFFECTS ASSOCIATED WITH OPHTHALMIC DRUG USAGE

2.10. MARKET OPPORTUNITIES

2.10.1. SURGE IN INTEREST REGARDING TOPICALLY ADMINISTERED OPHTHALMIC DRUGS

2.10.2. INCREASE IN APPROVALS FOR INNOVATIVE OPHTHALMIC THERAPIES

2.11. ANALYST PERSPECTIVE

3.    EUROPE OPHTHALMIC DRUGS MARKET – BY TYPE

3.1. PRESCRIPTION DRUGS

3.2. OVER-THE-COUNTER DRUGS

4.    EUROPE OPHTHALMIC DRUGS MARKET – BY CONDITION

4.1. DRY EYE

4.2. GLAUCOMA

4.3. INFECTION/INFLAMMATION/ALLERGIES

4.4. RETINAL DISORDER

4.4.1. WET-AGE RELATED MACULAR DEGENERATION

4.4.2. DRY-AGE RELATED MACULAR DEGENERATION

4.4.3. DIABETIC RETINOPATHY

4.4.4. OTHER RETINAL DISORDERS

4.5. OTHER CONDITIONS

5.    EUROPE OPHTHALMIC DRUGS MARKET – BY THERAPEUTIC TYPE

5.1. ANTI-GLAUCOMA

5.2. ANTI-INFECTION

5.3. ANTI-INFLAMMATORY

5.4. ANTI-ALLERGY

5.5. OTHER THERAPEUTIC TYPES

6.    EUROPE OPHTHALMIC DRUGS MARKET – BY DELIVERY METHOD

6.1. GELS

6.2. EYE SOLUTIONS & SUSPENSIONS

6.3. CAPSULES & TABLETS

6.4. EYE DROPS

6.5. OINTMENTS

7.    EUROPE OPHTHALMIC DRUGS MARKET – BY CHANNEL

7.1. HOSPITAL PHARMACIES

7.2. DRUG STORES

7.3. ONLINE PHARMACIES

7.4. OTHER CHANNELS

8.    EUROPE OPHTHALMIC DRUGS MARKET – COUNTRY OUTLOOK

8.1. UNITED KINGDOM

8.1.1. UNITED KINGDOM OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.2. GERMANY

8.2.1. GERMANY OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.3. FRANCE

8.3.1. FRANCE OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.4. ITALY

8.4.1. ITALY OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.5. SPAIN

8.5.1. SPAIN OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.6. POLAND

8.6.1. POLAND OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.7. REST OF EUROPE

8.7.1. REST OF EUROPE OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

9.    COMPETITIVE LANDSCAPE

9.1. ABBVIE INC

9.1.1. OVERVIEW

9.1.2. PRODUCT PORTFOLIO

9.1.3. KEY STRENGTHS

9.1.4. KEY CHALLENGES

9.2. BAUSCH HEALTH COMPANIES INC

9.2.1. OVERVIEW

9.2.2. PRODUCT PORTFOLIO

9.2.3. KEY STRENGTHS

9.2.4. KEY CHALLENGES

9.3. JOHNSON & JOHNSON

9.3.1. OVERVIEW

9.3.2. PRODUCT PORTFOLIO

9.3.3. KEY STRENGTHS

9.3.4. KEY CHALLENGES

9.4. NOVARTIS AG

9.4.1. OVERVIEW

9.4.2. PRODUCT PORTFOLIO

9.4.3. KEY STRENGTHS

9.4.4. KEY CHALLENGES

9.5. REGENERON PHARMACEUTICALS INC

9.5.1. OVERVIEW

9.5.2. PRODUCT PORTFOLIO

9.5.3. KEY STRENGTHS

9.5.4. KEY CHALLENGES

9.6. SUN PHARMACEUTICAL INDUSTRIES LTD

9.6.1. OVERVIEW

9.6.2. PRODUCT PORTFOLIO

9.6.3. KEY STRENGTHS

9.6.4. KEY CHALLENGES

9.7. ACCUTOME INC

9.7.1. OVERVIEW

9.7.2. PRODUCT PORTFOLIO

9.7.3. KEY STRENGTHS

9.7.4. KEY CHALLENGES

9.8. GENENTECH INC

9.8.1. OVERVIEW

9.8.2. PRODUCT PORTFOLIO

9.8.3. KEY STRENGTHS

9.8.4. KEY CHALLENGES

9.9. THEA PHARMA INC

9.9.1. OVERVIEW

9.9.2. PRODUCT PORTFOLIO

9.9.3. KEY STRENGTHS

9.9.4. KEY CHALLENGES

9.10. PFIZER INC

9.10.1. OVERVIEW

9.10.2. PRODUCT PORTFOLIO

9.10.3. KEY STRENGTHS

9.10.4. KEY CHALLENGES

10. RESEARCH METHODOLOGY & SCOPE

10.1. RESEARCH SCOPE & DELIVERABLES

10.2. SOURCES OF DATA

10.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: LIST OF COLLABORATIONS

TABLE 4: LIST OF PRODUCT LAUNCHES

TABLE 5: LIST OF MERGERS & ACQUISITIONS

TABLE 6: EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

TABLE 7: EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $ MILLION)

TABLE 8: EUROPE OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $ MILLION)

TABLE 9: EUROPE OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)

TABLE 10: EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030 (IN $ MILLION)

TABLE 11: EUROPE OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030 (IN $ MILLION)

TABLE 12: EUROPE OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $ MILLION)

List of Figures

FIGURE 1: TECHNOLOGY SNAPSHOT

FIGURE 2: MARKET MATURITY ANALYSIS

FIGURE 3: EUROPE OPHTHALMIC DRUGS MARKET, BY TYPE, 2022 & 2030 (IN %)

FIGURE 4: EUROPE OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS, 2023-2030 (IN $ MILLION)

FIGURE 5: EUROPE OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER DRUGS, 2023-2030 (IN $ MILLION)

FIGURE 6: EUROPE OPHTHALMIC DRUGS MARKET, BY CONDITION, 2022 & 2030 (IN %)

FIGURE 7: EUROPE OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2030 (IN $ MILLION)

FIGURE 8: EUROPE OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2030 (IN $ MILLION)

FIGURE 9: EUROPE OPHTHALMIC DRUGS MARKET, BY INFECTION/INFLAMMATION/ALLERGIES, 2023-2030 (IN $ MILLION)

FIGURE 10: EUROPE OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)

FIGURE 11: EUROPE OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2022 & 2030 (IN %)

FIGURE 12: EUROPE OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)

FIGURE 13: EUROPE OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)

FIGURE 14: EUROPE OPHTHALMIC DRUGS MARKET, BY DIABETIC RETINOPATHY, 2023-2030 (IN $ MILLION)

FIGURE 15: EUROPE OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL DISORDERS, 2023-2030 (IN $ MILLION)

FIGURE 16: EUROPE OPHTHALMIC DRUGS MARKET, BY OTHER CONDITIONS, 2023-2030 (IN $ MILLION)

FIGURE 17: EUROPE OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2022 & 2030 (IN %)

FIGURE 18: EUROPE OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA, 2023-2030 (IN $ MILLION)

FIGURE 19: EUROPE OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION, 2023-2030 (IN $ MILLION)

FIGURE 20: EUROPE OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY, 2023-2030 (IN $ MILLION)

FIGURE 21: EUROPE OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY, 2023-2030 (IN $ MILLION)

FIGURE 22: EUROPE OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC TYPES, 2023-2030 (IN $ MILLION)

FIGURE 23: EUROPE OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2022 & 2030 (IN %)

FIGURE 24: EUROPE OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2030 (IN $ MILLION)

FIGURE 25: EUROPE OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS & SUSPENSIONS, 2023-2030 (IN $ MILLION)

FIGURE 26: EUROPE OPHTHALMIC DRUGS MARKET, BY CAPSULES & TABLETS, 2023-2030 (IN $ MILLION)

FIGURE 27: EUROPE OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2030 (IN $ MILLION)

FIGURE 28: EUROPE OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2030 (IN $ MILLION)

FIGURE 29: EUROPE OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2022 & 2030 (IN %)

FIGURE 30: EUROPE OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES, 2023-2030 (IN $ MILLION)

FIGURE 31: EUROPE OPHTHALMIC DRUGS MARKET, BY DRUG STORES, 2023-2030 (IN $ MILLION)

FIGURE 32: EUROPE OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES, 2023-2030 (IN $ MILLION)

FIGURE 33: EUROPE OPHTHALMIC DRUGS MARKET, BY OTHER CHANNELS, 2023-2030 (IN $ MILLION)

FIGURE 34: EUROPE OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2022 & 2030 (IN %)

FIGURE 35: UNITED KINGDOM OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 36: GERMANY OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 37: FRANCE OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 38: ITALY OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 39: SPAIN OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 40: POLAND OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 41: REST OF EUROPE OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying